Fox Run Management L.l.c. buys $1,175,616 stake in Hologic (HOLX)

Hologic (HOLX) : Fox Run Management L.l.c. scooped up 23,600 additional shares in Hologic during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 18, 2016. The investment management firm now holds a total of 31,400 shares of Hologic which is valued at $1,175,616.Hologic makes up approximately 0.76% of Fox Run Management L.l.c.’s portfolio.

Hologic closed down -0.06 points or -0.16% at $37.44 with 33,78,011 shares getting traded on Friday. Post opening the session at $37.5, the shares hit an intraday low of $37.29 and an intraday high of $37.7 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , New York State Teachers Retirement System boosted its stake in HOLX in the latest quarter, The investment management firm added 27,011 additional shares and now holds a total of 481,810 shares of Hologic which is valued at $18,038,966. Hologic makes up approx 0.05% of New York State Teachers Retirement System’s portfolio. Oakbrook Investments sold out all of its stake in HOLX during the most recent quarter. The investment firm sold 22,100 shares of HOLX which is valued $799,357.Dnb Asset Management As reduced its stake in HOLX by selling 800 shares or 6.06% in the most recent quarter. The Hedge Fund company now holds 12,405 shares of HOLX which is valued at $448,689. Hologic makes up approx 0.01% of Dnb Asset Management As’s portfolio.

On the company’s financial health, Hologic reported $0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Jan 27, 2016. Analyst had a consensus of $0.42. The company had revenue of $695.20 million for the quarter, compared to analysts expectations of $688.80 million. The company’s revenue was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.39 EPS.

Many Wall Street Analysts have commented on Hologic. Needham Upgraded Hologic on Jan 28, 2016 to ” Buy”, Price Target of the shares are set at $41.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.